

ARD

Annals of the Rheumatic Diseases
The EULAR Journal

Editor

Leo van de Putte (Nijmegen)

Associate editors

Thomas Bardin (Paris)
Johannes Bijlsma (Utrecht)
Gerd Burmester (Berlin)
Bevrah Hahn (Los Angeles)
Frank Wollheim (Lund)
Anthony Woolf (Truro)

Methodological adviser

Paco Welens (Nijmegen)

Editorial board

Martin Aringer (Vienna)
Paul Bacon (Birmingham)
Francis Berenbaum (Paris)
Maarten Boers (Amsterdam)
Dimitrios Boumpas (Heraklion)
Barry Bresnihan (Dublin)
Hillary Capell (Glasgow)
Maurizio Cutolo (Genova)
Gary Firestein (La Jolla San Diego)
Philippe Goupille (Tours)
Ellen Gravellese (Boston)
Wolfgang Gross (Bad Bramstedt)
Francis Guillemain (Nancy)
Gabriel Herrero-Beaufort (Madrid)
Frederic Houssiau (Brussels)
Tom Huizinga (Leiden)
Christian Jorgensen (Montpellier)
George Kolllias (Athens)
Tore Kvien (Oslo)
Marjatta Leirisalo-Repo (Lund)
Frank Luijten (Leuven)
Hanns-Martin Lorenz (Heidelberg)

W Maslinski (Poland)
Marco Matucci Cerinic (Florence)
Kusuki Nishioka (Kanagawa)
Seza Özgen (Ankara)
Thomas Pap (Magdeburg)
Eliseo Pascual Gómez (Alicante)
Leonardo Punzi (Padova)
Lars Rönnblom (Uppsala)
Blaž Rozman (Ljubljana)
Georg Schett (Vienna)
José Da Silva (Coimbra)
Hendrik Schulze-Koops (Erlangen)
Alex So (Lausanne)
Tuulikki Sokka (Nashville)
Deborah Symmons (Manchester)
Paul-Peter Tak (Amsterdam)
Alan Tyndall (Basel)
Athanasios Tzioufas (Athens)
Jiří Vencovsky (Praag)
Michael Ward (Bethesda)
Michael Weisman (Los Angeles)
Hasan Yazici (Istanbul)
Editor, BMJ

Advisory committee

Wim vd Berg (Nijmegen)
Stefano Bombardieri (Pisa)
Ferdinand Breedveld (Leiden)
Leslie Crofford (Michigan)
Jean-Michel Dayer (Geneva)
Mike Doherty (Nottingham)
Maxime Dougados (Paris)
John Edmonds (Sydney)
Paul Emery (Leeds)
Daniel Furst (Seattle)
Steffen Gay (Zurich)
Joachim Kalden (Erlangen)
Edward Keystone (Toronto)
Lars Klareskog (Stockholm)

Peter Lipsky (Dallas)
Stefan Lohmander (Lund)
Ravinder Maini (London)
Emilio Martin Mola (Madrid)
Haralampus Moutsopoulos (Athens)
James O'Dell (Omaha)
Karel Pavelka (Prague)
Josef Rovensky (Piestany)
Yehuda Shoenfeld (Tel-Hashomer)
Josef Smolen (Vienna)
Walther van Venrooy (Nijmegen)
Eric Veys (Gent)
Allan Wiik (Denmark)

Instructions to authors

Full instructions are available online at www.annrheumdis.com/misc/ifora.shtml
If you do not have web access please contact the editorial office:
Email: annrheumdis.edoff@worldonline.nl

Subscription information


See inside back cover

Copyright

© 2004 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*.

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at www.annrheumdis.com/misc/ifora.shtml

- *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Thanet Press, Margate
- Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



contents ARD

Volume 63 Supplement II November 2004

Preface

- ii1 Advances in targeted therapies VI F C Breedveld, J R Kalden, J S Smolen

Consensus statement

- ii2 Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNF α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004 D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, P J Mease

Warm-up

- ii13 Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues F Wolfe, K Michaud, E M DeWitt
- ii18 Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection L H Calabrese, N Zein, D Vassilopoulos

Genetics

- ii25 Pharmacogenetics in the rheumatic diseases B N Cronstein
- ii28 What precedes development of rheumatoid arthritis? L Klareskog, L Alfredsson, S Rantapää-Dahlqvist, E Berglin, P Stolt, L Padyukov

Clinical aspects

- ii32 Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? T Pincus, T Sokka
- ii40 The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning G Stucki, A Cieza
- ii46 Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? S M Carty, N Snowden, A J Silman
- ii50 New issues in tuberculosis S H E Kaufmann

New targets I—signal transduction

- ii57 Nuclear factor (NF)- κ B proteins: therapeutic targets I M Verma
- ii62 Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs M Karin
- ii65 B cell signalling as therapeutic target R H Carter
- ii67 Targeting the Jak/STAT pathway for immunosuppression J J O'Shea

New targets II

- ii72 DREAMing about arthritic pain H-Y M Cheng, J M Penninger

.....	ii90	Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways <i>C Ospelt, D Kyburz, M Pierer, R Seibl, M Kurowska, O Distler, M Neidhart, U Muller-Ladner, T Pap, R E Gay, S Gay</i>
New targets III—pathways		
ii76 A toll for T cell costimulation <i>F Y Liew, M Komai-Koma, D Xu</i>		
.....	ii92	Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease <i>C D Buckley, A Filer, O Haworth, G Parsonage, M Salmon</i>
New target disease		
ii79 The utility of tumour necrosis factor blockade in orphan diseases <i>E C Keystone</i>		
.....	ii96	Cell therapy for autoimmune diseases: does it have a future? <i>A Radbruch, A Thiel</i>
New targets IV		
ii84 Chemokines: role in inflammation and immune surveillance <i>B Moser, K Willimann</i>		